Chronic Inflammatory Rheumatism: Management of Comorbidities in Ambulatory Medicine
NCT ID: NCT05613712
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
229 participants
OBSERVATIONAL
2023-02-11
2023-05-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients followed by the rheumatology department of the CHU Grenoble Alpes, constituting the SCORIC group
Patients
Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
Referring physician
Physicians identified as the referring physician for patients in the SCORIC group
Referring physician
Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patients
Description by the patients through the questionnaire of the elements limiting the good ambulatory follow-up
Referring physician
Description by the referring physicians through the questionnaire of the elements limiting the applicability of the recommendations issued by the rheumatology department of the CHU Grenoble Alpes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* men and women over 18 years of age
* Informed volunteers who have consented to participate in the study
* have rheumatoid arthritis, spondyloarthritis or psoriatic arthritis
* have been hospitalised in a day hospital in the rheumatology department of the Grenoble-Alpes University = SCORIC cohort of the department
* Cohort of referring physicians :
* volunteers who received informed information and consented to participate in the study
* be the referring physician of a patient of the SCORIC cohort of the rheumatology department of the South Hospital of the CHU Grenoble-Alpes
Exclusion Criteria
* psychiatric pathologies or history of behavioural disorders
* persons referred to in articles L1121-5 to L1121-8 of the Public Health Code
* persons under guardianship or curatorship
* not affiliated to the social security system
* minors
* Refusal to participate by the patient and/or unreturned questionnaire
* Cohort of referring physicians:
* the physician is no longer the patient's referring physician
* refusal of the doctor to participate and/or questionnaire not returned
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xavier ROMAND, PHD
Role: PRINCIPAL_INVESTIGATOR
CHU Grenoble Alpes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Grenoble Alpes
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lagadou A, Gastaldi R, Vacher L, Baillet A. Gender influences adhesion to recommendations for optimal comorbidity screening and management of patients with chronic inflammatory rheumatic diseases starting a biological disease-modifying antirheumatic drug. RMD Open. 2024 Nov 11;10(4):e004364. doi: 10.1136/rmdopen-2024-004364. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC22.0355
Identifier Type: -
Identifier Source: org_study_id